Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




May
30
Today In Oncology
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
Behind the Scenes of the 2026 ASCO Annual Meeting
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo